

Pierre-Eric Juif

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4741209/publications.pdf>

Version: 2024-02-01

27
papers

518
citations

687363

13
h-index

677142

22
g-index

27
all docs

27
docs citations

27
times ranked

606
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P ₁ Receptor Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects. <i>Clinical and Translational Science</i> , 2021, 14, 143-147.	3.1	4
2	Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y ₁₂ Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. <i>Thrombosis and Haemostasis</i> , 2021, 121, 755-766.	3.4	9
3	PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 213-224.	1.8	5
4	Modelling pharmacokinetics and pharmacodynamics of the selective S1P ₁ receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 791-800.	2.4	4
5	Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan. <i>AAPS Journal</i> , 2020, 22, 103.	4.4	4
6	Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm. <i>Frontiers in Pharmacology</i> , 2020, 11, 628956.	3.5	8
7	Clinical Pharmacology of the Reversible and Potent P2Y ₁₂ Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male Subjects. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 123-130.	2.0	27
8	Cardiodynamic Interactions between Two S1P ₁ Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3232.	4.1	7
9	Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan. <i>Clinical and Translational Science</i> , 2019, 12, 440-444.	3.1	4
10	First use of cenerimod, a selective S1P ₁ receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. <i>Lupus Science and Medicine</i> , 2019, 6, e000354.	2.7	35
11	Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1022-1029.	4.7	52
12	Pharmacological rescue of nociceptive hypersensitivity and oxytocin analgesia impairment in a rat model of neonatal maternal separation. <i>Pain</i> , 2018, 159, 2630-2640.	4.2	20
13	Effects of multiple-dose ponesimod, a selective S1P ₁ receptor modulator, on lymphocyte subsets in healthy humans. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 123-131.	4.3	12
14	Absolute Bioavailability of Ponesimod, a Selective S1P ₁ Receptor Modulator, in Healthy Male Subjects. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 129-134.	1.6	8
15	Metabolite profiling in early clinical drug development: current status and future prospects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 803-806.	3.3	27
16	A pharmacokinetic drug-drug interaction study between selezipag and midazolam, a CYP3A4 substrate, in healthy male subjects. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1121-1128.	1.9	14
17	Mitigation of Initial Cardiodynamic Effects of the S1P ₁ Receptor Modulator Ponesimod Using a Novel Up-titration Regimen. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 401-410.	2.0	16
18	Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P ₁ Receptor Modulator in Healthy Subjects. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2636.	4.1	13

#	ARTICLE	IF	CITATIONS
19	Peripheral and central alterations affecting spinal nociceptive processing and pain at adulthood in rats exposed to neonatal maternal deprivation. <i>European Journal of Neuroscience</i> , 2016, 44, 1952-1962.	2.6	17
20	Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 879-895.	3.3	49
21	Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects. <i>Drugs in R and D</i> , 2015, 15, 203-210.	2.2	8
22	A Novel Gradual Up-Titration Regimen Mitigates The First-Dose Effects Of Ponesimod, A Selective S1p1 Receptor Modulator. <i>Clinical Therapeutics</i> , 2015, 37, e36-e37.	2.5	4
23	Corticosterone analgesia is mediated by the spinal production of neuroactive metabolites that enhance <scp>GABA</scp>ergic inhibitory transmission on dorsal horn rat neurons. <i>European Journal of Neuroscience</i> , 2015, 41, 390-397.	2.6	17
24	Etifoxine analgesia in experimental monoarthritis: A combined action that protects spinal inhibition and limits central inflammatory processes. <i>Pain</i> , 2014, 155, 403-412.	4.2	18
25	Neurohormonal effects of oxytocin and vasopressin receptor agonists on spinal pain processing in male rats. <i>Pain</i> , 2013, 154, 1449-1456.	4.2	78
26	Long-Lasting Spinal Oxytocin Analgesia Is Ensured by the Stimulation of Allopregnanolone Synthesis Which Potentiates GABAA Receptor-Mediated Synaptic Inhibition. <i>Journal of Neuroscience</i> , 2013, 33, 16617-16626.	3.6	42
27	Pain behavior and spinal cell activation due to carrageenan-induced inflammation in two inbred rat strains with differential hypothalamicâ€“pituitaryâ€“adrenal axis reactivity. <i>Physiology and Behavior</i> , 2012, 105, 901-908.	2.1	16